Many studies and reports have been analyzed including “Pharmacotherapy - 2012 - Koleba - Pharmacokinetics of Intravenous Immunoglobulin A Systematic Review” and “Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)”. Research conducted by Zbrozek et. al found that a greater number of infections was noted in the time period greater than 18 days after infusion, with higher rates of health care utilization over a period of seven months. It’s known that serum IgG levels increased by approximately 2.5 g/L for every 0.1 g/kg of IGIV infused. It’s also known that patients on average are most susceptible to opportunistic infections during their trough period. If we can increase the IgG levels by 2-5%, that could mean the difference between getting an infection or not. We know how much just one hospitalization costs payers so the hope is to decrease the risk for hospitalizations with that extra 2-5% that is currently wasted.

Speaking to the increased demand for plasma-derived medications. Please see the attached report titled “HLC201C-Report-Oveview” and this article, “https://www.grandviewresearch.com/industry-analysis/us-intravenous-immunoglobulin-ivig-market”. These reports speak to the increased demand of plasma. This goes well beyond IVIG.

By embracing our medical device and facilitating its utilization through appropriate coverage and reimbursement policies, insurance companies and payers reinforce their commitment to affordable and accessible healthcare. By recognizing its value and impact, these important stakeholders further their mission of serving their policyholders with the highest standards of care.
Join us in revolutionizing healthcare delivery. Together, we can make a significant difference in improving patient outcomes, enhancing cost-effectiveness, and ensuring a brighter future for all, while continuing to foster innovation and progress in the ever-evolving realm of healthcare.